Open AccessCanakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial
Author(s) -
Helen Lachmann,
Bernard Lauwerys,
Paivi Miettunen,
Tilmann Kallinich,
Annette Jansson,
Itzhak Rosner,
Raffaele Manna,
Sara Murías,
Sinisa Savic,
Serge J. Smeets,
Fabrizio De Benedetti,
Anna Simon
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/e92f7o
Subject(s) - medicine , canakinumab , psychosocial , familial mediterranean fever , quality of life (healthcare) , population , cluster randomised controlled trial , pediatrics , physical therapy , cluster (spacecraft) , randomized controlled trial , disease , psychiatry , anakinra , environmental health , nursing , computer science , programming language
To evaluate the effect of canakinumab on health-related quality of life (HRQoL), work/school and social life of patients with autoinflammatory recurrent fever syndromes, including colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, and tumour necrosis factor receptor-associated periodic syndrome, in the CLUSTER trial.